Biomarkers for Diagnosis of Lung Nodules

Lung Abscess Clinical Trial

— Nodule  

Official title:

Biomarkers for Diagnosis of Lung Nodules

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01085864
• Other study ID #: 09-1106.cc
• Status: Recruiting
• Start date: March 17, 2010
• Est. completion date: October 1, 2027

Study information

• Verified date: March 2024
• Source: University of Colorado, Denver
• Contact: Brandi K Kubala
• Phone: 303-724-1657
• Email: brandi.kubala[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A need exists for non-invasive testing to aid in clinical decision-making for Computerized Tomography (CT) scan detected lung nodules of indeterminate etiology. The investigators hypothesize that biomarkers detectable in blood, sputum or urine may be useful for guiding clinical decisions in the setting of CT detected lung nodules to determine which nodules are malignant and which are benign. The investigators also hypothesize that these biomarkers will decrease in concentration to the normal range after successful surgical treatment of malignant lung nodules.

Description:

The Biomarkers for Diagnosis of Lung Nodules Study is a prospective study of a cohort of 500 individuals with lung nodules of indeterminate etiology that are identified by CT scans. Either biopsy or repeat CT scans must be clinically indicated to determine the etiology of the nodule. Patients will be asked to allow investigators access to CT scan images and spirometry data, and provide blood, sputum, urine, and exhaled breath samples over the course of the study. Patients will also be asked to allow investigators to access pathology records if a biopsy or surgical excision of the nodule is clinically indicated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 550
• Est. completion date: October 1, 2027
• Est. primary completion date: November 1, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Adult 18-85 years of age

2. Patients referred to pulmonologists, oncologists, or thoracic surgeons for the evaluation of peripheral lung nodules found on CT scan.

3. Repeat CT scans, biopsy or surgical excision are clinically indicated to determine the etiology of the nodule.

4. One or more lung nodules must be between 8 mm and 30 mm in the greatest diameter.

5. Patients must be fully informed of the investigational nature of the procedure and sign an informed consent.

-

Exclusion Criteria:

1. Lung nodules or masses greater than 30 mm in the greatest dimension.

2. Lung nodules that have solid calcification.

3. Lung nodules or masses with CT evidence of partial or complete obstruction of a lobar bronchus, main stem bronchus or the trachea.

4. No prior cancer with the exception of non-melanoma skin cancer.

5. Life expectancy of < 6 months

6. Any individual who does not give oral and written consent for participation -

Related Conditions & MeSH terms

• Lung Abscess

Locations

Country	Name	City	State
United States	University of Colorado Anschutz Medical Campus	Aurora	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
University of Colorado, Denver

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of biomarkers in blood, sputum or urine.	The primary hypothesis is that biomarkers detectable in blood, sputum, or urine will be useful for guiding clinical decisions in the setting of CT detected lung nodules.	Baseline, 3-6 months, 12 months, 24 months, time of biopsy or surgery (if applicable), and 6 months post surgery (if applicable).
Secondary	Evaluation of biomarkers after successful surgical treatment of malignant lung nodules.	The secondary hypothesis is that these biomarkers will decrease in concentration to the normal range after successful surgical treatment of malignant lung nodules.	Within 3 years